Navigation Links
Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study
Date:7/22/2009

DOYLESTOWN, Pa., July 22 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) www.quigleyco.com, today announced the results from its Phase IIb double-blind, placebo-controlled, study of topical compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. The study was completed with fewer than expected evaluable patients with the final and comprehensive conclusions revealing that (i) the compound is safe and well tolerated, and (ii) there were nominal trends, but no statistical differences, between active and placebo groups for the primary and secondary endpoints measuring efficacy by (a) the reduction of pain, (b) symptomatic improvements, (c) improved quality of life and (d) improved sleep.

However, the Company is encouraged by the positive, clinical and statistically significant improvement for efficacy in sural nerve conduction velocity and amplitude unexpectedly found in a sub-set of the patient population, announced in a press release on April 30, 2009. Those data may indicate the potential benefit of this compound as a disease modifying agent which, if validated through additional clinical trials, potentially broadens the therapeutic market opportunity. Additional clinical work would be required and future study considerations might include, a longer duration period to improve patient compliance as well as an assessment of sural nerve function and measures of distal nerve sensory thresholds in the feet to provide more detail to the potential for disease modification. There can be no assurance the Company will undertake additional clinical studies or that the results thereof would lead to a marketable product that can achieve regulatory approvals.

A prel
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
2. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
3. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
4. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
5. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
6. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
7. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
8. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
9. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW YORK, NY (September 16, 2014) The ... received the 2014 Higher Education Excellence in Diversity ... oldest and largest diversity-focused publication in higher education. ... national honor recognizing U.S. colleges and universities that ... will be featured along with 82 other recipients ...
(Date:9/16/2014)... Orange, NJ. September 16, 2014. Kessler Foundation researchers ... slowed processing speed in the executive deficits found ... slowed processing speed account for executive deficits in ... neuroimaging," was published online ahead of print on ... The authors are Victoria Leavitt, PhD, of ...
(Date:9/16/2014)... judges are the unwitting focus of some of Australia,s ... to improve their performance in competition, thanks to a ... Dr Daniel Greenwood, from QUT,s Institute of Health and ... Sport Centre of Excellence for Applied Sport Science Research, ... such as cricket, long jump, triple jump and pole ...
(Date:9/16/2014)... San Francisco, September 15, 2014 For patients with ... and stereotactic ablative radiation (SABR) may be a ... surgery that may not otherwise be an option, ... Society for Radiation Oncology,s (ASTRO,s) 56th Annual Meeting. ... for individuals with pancreatic ductal adenocarcinoma (PDA), the ...
(Date:9/16/2014)... be presented at the ESMO 2014 Congress will be ... (CEST) to give you a first glimpse of what ... under the leading theme Precision Medicine in Cancer Care. ... therapy is now possible for an increasing number of ... towards a common goal --improved patient outcomes. This is ...
Breaking Medicine News(10 mins):Health News:Columbia University College of Dental Medicine receives diversity award 2Health News:Columbia University College of Dental Medicine receives diversity award 3Health News:Columbia University College of Dental Medicine receives diversity award 4Health News:Getting the jump on competitors: QUT study 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 2Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 3Health News:Chemotherapy and SABR consecutively may be promising treatment option for advanced pancreatic cancer 4Health News:ESMO 2014 Congress Preview 2
... School of Medicine has helped confirm the reliability of ... individual's genetic makeup. ,The Stanford group was ... the genetic test can identify patients who are at ... infection. That means high-risk patients could be directed toward ...
... A report released by the Australian Institute of Health ... in Queensland. Nearly 20 to 50% of the population ... to be relying on anti-depressants heavily. ... affair in Queensland where nearly 11,500 prescriptions for anti ...
... today has become the number one killer. More so, related ... occupational Hazard// with millions of people running the risk of ... fibers and second hand smoker are the major causes of ... from exposure to benzene from the dye, drugs, pesticides and ...
... the world. There is also a rise of alcohol abuse ... women says that in women cognitive problems develop faster in ... subject to physical changes in the brain more rapidly than ... at the research institute RTI at the university in Baltimore ...
... Institute of Medicine released a report recommending nutrition ... school environment, such as a la carte cafeteria ... Dairy Council (NDC) applauds the overall recommendations outlined ... nonfat and low-fat dairy products, fruits, vegetables and ...
... An international research team, led by investigators from the ... Institute (DFCI), has found// a new way that some ... drugs like Iressa and Tarceva. Their report, which will ... online release, describes a totally new resistance mechanism that ...
Cached Medicine News:Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 2Health News:New Test Helps Identify Hepatitis C Patients at High Risk of Developing Cirrhosis 3Health News:Today Cancer is the Deadliest Killer 2Health News:Alcoholism Develops Cognitive Problems in Women 2Health News:National Academy of Sciences' Institute of Medicine Report Calls for More Dairy Foods at School 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 2Health News:New Mechanism Identified for Resistance to Targeted Lung Cancer Drugs 3
(Date:9/16/2014)... 2014  DNAtrix, Inc., experts in oncolytic virus ... treated with the company,s lead product, DNX-2401, a ... randomized, multicenter, open-label Phase Ib study for patients ... with leading neurosurgeons and neuro-oncologists in the US, ... randomized Phase Ib study of DNX-2401 at Moffitt ...
(Date:9/16/2014)... 16, 2014  Eli Lilly and Company (NYSE: ... an agreement to co-develop and commercialize AZD3293, an ... in development as a potential treatment for Alzheimer,s ... is characterized by the accumulation of amyloid plaque ... with the development of beta-amyloid. Inhibiting BACE is ...
(Date:9/15/2014)... Sept. 16, 2014  Bayer HealthCare and Orion ... Finland , have begun to enroll ... an investigational oral androgen receptor inhibitor in clinical ... men with castration-resistant prostate cancer who have rising ... metastases. The trial is designed to determine the ...
Breaking Medicine Technology:DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3
... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that ... at the Lazard Capital Markets 8th Annual Healthcare Conference, being ... Bentsur,s presentation is scheduled to take place on Wednesday, November ... audio webcast of Mr. Bentsur,s presentation will be accessible from ...
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3
... Innovations' Instrument Manager (IM) is an instrument ... system that enables laboratories to work more ... as a data management solution that stands ... information system, filling those important gaps in ...
... These color vision tests have been designed ... the type and estimating the grade of ... measure Red, Green, Blue, Yellow. They provide ... deficiencies. Screening is accomplished using the initial ...
... sets are designed to indicate color deficiency ... is used to separate Medium and Strong ... test is much more difficult and is ... Both of these tests provide basic ...
Single Use Loading Units with Titanium Staplers for use with MULTIFIRE ENDO TA™ 30 12 mm (Single Use Staplers with Titanium Staplers)....
Medicine Products: